Written by Amanda Bates, RN and medically reviewed by Dr
This discovery relates to the simultaneous use of the peptide with at least one of the umbilical cord/placental blood, plasma, mesenchymal stem cells (MSCs), and/or mono-nucleated cells (MNCs) in the treatment of ocular diseases, including dry eye, inflammation, oxidative stress, and eye injury)
It was engineered isolate hGHs lipolytic (fat-breaking) properties without activating the growth hormone receptor or increasing IGF-1. The design allows it to mimic hGHs metabolic domain in a shorter, more stable form
Before you go ahead with any treatment, always make sure your provider is a registered and qualified healthcare professional
Worth flagging again: the published research on TB-500 specifically, as distinct from full thymosin beta-4, is thinner than the BPC-157 literature